


## $\alpha$ -Glucosidase-IN-30

Cat. No.:	HY-155105
CAS No.:	2966859-35-6
Molecular Formula:	C <sub>20</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>
Molecular Weight:	389.41
Target:	Glucosidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	$\alpha$ -Glucosidase-IN-30 (compound 8c) is a potent, orally active, competitive inhibitor against $\alpha$ -glucosidase, with $K_i$ of 40.0 $\mu$ M and $IC_{50}$ value of 49.0 $\mu$ M. $\alpha$ -Glucosidase-IN-30 is non-cytotoxic against the cancer and normal cell lines MCF-7 and HDF, and can be used for Type 2 diabetes study <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	49.0 $\mu$ M ( $\alpha$ -glucosidase)
<b>In Vitro</b>	$\alpha$ -Glucosidase-IN-30 (compound 8c) shows no cytotoxic activity against the cancer and normal cell lines MCF-7 and HDF ( $IC_{50} > 200 \mu$ M), respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Yousefnejad F, et al. Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting  $\alpha$ -glucosidase. Sci Rep. 2023;13(1):12397.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA